NeuroBo Pharmaceuticals Stock (NASDAQ:NRBO)
Previous Close
$2.32
52W Range
$2.08 - $6.75
50D Avg
$2.90
200D Avg
$3.89
Market Cap
$21.11M
Avg Vol (3M)
$45.47K
Beta
-0.28
Div Yield
-
NRBO Company Profile
NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company provides therapies for neurodegenerative, infectious, and cardiometabolic diseases. Its therapeutics programs include ANA001, an oral niclosamide formulation, which is in Phase 2/3 clinical trials to treat patients with moderate coronavirus disease (COVID-19); NB-01 for the treatment of painful diabetic neuropathy; NB-02 to treat the symptoms of cognitive impairment and modify the progression of neurodegenerative diseases associated with the malfunction of tau protein; and Gemcabene, an acute indication for COVID-19. NeuroBo Pharmaceuticals, Inc. is headquartered in Boston, Massachusetts.